Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACHN
CUSIP00448Q20
Phone203-624-7000
Debt
Debt-to-Equity RatioN/A
Current Ratio35.95
Quick Ratio35.95
Price-To-Earnings
Trailing P/E Ratio-4.15
Forward P/E Ratio-4.83
P/E GrowthN/A
Sales & Book Value
Annual Sales$15 million
Price / Sales23.65
Cash FlowN/A
Price / CashN/A
Book Value$2.35 per share
Price / Book1.09
Profitability
EPS (Most Recent Fiscal Year)($0.62)
Net Income$-85,230,000.00
Net MarginsN/A
Return on Equity-25.26%
Return on Assets-24.41%
Miscellaneous
Employees88
Outstanding Shares138,590,000
Market Cap$370.02 million
Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions
What is Achillion Pharmaceuticals' stock symbol?
Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."
How were Achillion Pharmaceuticals' earnings last quarter?
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.01. View Achillion Pharmaceuticals' Earnings History.
When is Achillion Pharmaceuticals' next earnings date?
What price target have analysts set for ACHN?
6 analysts have issued 12-month price objectives for Achillion Pharmaceuticals' stock. Their predictions range from $3.50 to $6.50. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $4.80 in the next year. This suggests a possible upside of 86.8% from the stock's current price. View Analyst Price Targets for Achillion Pharmaceuticals.
What is the consensus analysts' recommendation for Achillion Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.
Who are some of Achillion Pharmaceuticals' key competitors?
Some companies that are related to Achillion Pharmaceuticals include TESARO (TSRO), Myovant Sciences (MYOV), IMMURON Ltd/S (IMRN), Innoviva (INVA), Impax Laboratories (IPXL), Deciphera Pharmaceuticals (DCPH), ImmunoGen (IMGN), Alder Biopharmaceuticals (ALDR), Uniqure (QURE), Biohaven Pharmaceutical (BHVN), Wave Life Sciences (WVE), Esperion Therapeutics (ESPR), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX) and Athenex (ATNX).
Who are Achillion Pharmaceuticals' key executives?
Achillion Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph Truitt, Pres, CEO & Director (Age 53)
- Ms. Mary Kay Fenton, Exec. VP, CFO & Treasurer (Age 54)
- Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 63)
- Glenn Schulman, Exec. Director of Investor Relations
- Ms. Ky Nam-Wortman, Head of HR and VP
Has Achillion Pharmaceuticals been receiving favorable news coverage?
News stories about ACHN stock have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Achillion Pharmaceuticals earned a coverage optimism score of 0.00 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 47.13 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Achillion Pharmaceuticals.
Who are Achillion Pharmaceuticals' major shareholders?
Achillion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include RTW Investments LP (9.77%), BlackRock Inc. (8.58%), Dimensional Fund Advisors LP (4.98%), Baker BROS. Advisors LP (1.40%), DAFNA Capital Management LLC (0.68%) and Renaissance Technologies LLC (0.53%). Company insiders that own Achillion Pharmaceuticals stock include & Johnson Johnson, Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Institutional Ownership Trends for Achillion Pharmaceuticals.
Which institutional investors are selling Achillion Pharmaceuticals stock?
Which institutional investors are buying Achillion Pharmaceuticals stock?
ACHN stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, GSA Capital Partners LLP, BlackRock Inc., United Services Automobile Association, Spark Investment Management LLC, DAFNA Capital Management LLC, BlueMountain Capital Management LLC and Bank of America Corp DE. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Insider Buying and Selling for Achillion Pharmaceuticals.
How do I buy shares of Achillion Pharmaceuticals?
Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achillion Pharmaceuticals' stock price today?
One share of ACHN stock can currently be purchased for approximately $2.57.
How big of a company is Achillion Pharmaceuticals?
Achillion Pharmaceuticals has a market capitalization of $370.02 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-85,230,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Achillion Pharmaceuticals employs 88 workers across the globe.
How can I contact Achillion Pharmaceuticals?
Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.
MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
